| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | COL7 |
| Uniprot No | Q9C9A9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-392aa |
| 氨基酸序列 | MVVDVESRTA SVTGEKMAAR GCDACMKRSR ASWYCPADDA FLCQSCDASI HSANHLAKRH ERVRLQSSSP TETADKTTSV WYEGFRRKAR TPRSKSCAFE KLLQIESNDP LVPELGGDED DGFFSFSSVE ETEESLNCCV PVFDPFSDML IDDINGFCLV PDEVNNTTTN GELGEVEKAI MDDEGFMGFV PLDMDLEDLT MDVESLLEEE QLCLGFKEPN DVGVIKEENK VGFEINCKDL KRVKDEDEEE EEAKCENGGS KDSDREASND KDRKTSLFLR LDYGAVISAW DNHGSPWKTG IKPECMLGGN TCLPHVVGGY EKLMSSDGSV TRQQGRDGGG SDGEREARVL RYKEKRRTRL FSKKIRYEVR KLNAEQRPRI KGRFVKRTSL LT |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于COL7重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *Intravenous injection of recombinant human type VII collagen corrects skin disease in recessive dystrophic epidermolysis bullosa mice*
**作者**: Remington J, Wang X, Hou Y, et al.
**摘要**: 本研究通过静脉注射重组人VII型胶原蛋白(rhCOL7)到隐性营养不良性大疱性表皮松解症(RDEB)小鼠模型，证明rhCOL7能够靶向皮肤并形成功能性锚定纤维，显著改善皮肤脆弱性和水疱症状，为蛋白质替代疗法提供了临床前依据。
---
2. **文献名称**: *Recombinant collagen VII restores skin integrity in dystrophic epidermolysis bullosa*
**作者**: Woodley DT, Cogan J, Wang X, et al.
**摘要**: 该研究通过局部应用重组COL7蛋白至RDEB患者皮肤伤口，观察到COL7成功整合到真皮-表皮交界处，促进伤口愈合并减少炎症反应，首次在人体试验中验证了重组COL7的潜在治疗价值。
---
3. **文献名称**: *Production of functional recombinant human collagen VII in mammalian cells*
**作者**: Chen M, Marinkovich MP, Jones JC, et al.
**摘要**: 研究开发了一种基于哺乳动物细胞表达系统的高效生产重组人COL7蛋白的方法，验证了其正确折叠和形成三聚体的能力，并证实其在体外模型中恢复皮肤细胞黏附功能，为大规模制备治疗用COL7奠定了基础。
---
这些文献涵盖了COL7重组蛋白的动物模型治疗验证、临床试验及规模化生产方向，反映了其在遗传性皮肤病治疗中的关键进展。
Collagen type VII (COL7) is a critical structural protein encoded by the *COL7A1* gene, primarily responsible for anchoring the epidermis to the dermis. It forms the anchoring fibrils beneath the basement membrane zone, ensuring skin integrity by linking type IV collagen and other extracellular matrix components. Mutations in *COL7A1* lead to dystrophic epidermolysis bullosa (DEB), a rare genetic disorder characterized by fragile skin, blistering, and chronic wounds. Severe forms, like recessive DEB (RDEB), are often fatal due to complications like infections or aggressive squamous cell carcinoma.
Recombinant COL7 protein has emerged as a therapeutic strategy to restore functional collagen in DEB. Produced via mammalian cell cultures (e.g., CHO or HEK293 cells) or plant-based systems, recombinant COL7 mimics the natural protein’s structure, including its triple-helical collagenous domains and non-collagenous (NC1. NC2) regions critical for fibril assembly. Preclinical studies in DEB mouse models showed that intradermal or systemic delivery of recombinant COL7 integrates into the dermal-epidermal junction, stabilizing skin structure and reducing blistering.
Current research focuses on optimizing delivery methods—such as topical formulations, injectable hydrogels, or gene-corrected cell therapies—to enhance bioavailability and longevity. Early-phase clinical trials, including the use of engineered COL7 (e.g., BPN001/VII protein), demonstrate promising safety profiles and partial wound healing. Challenges remain, including immune responses against the recombinant protein, scalability of production, and ensuring sustained therapeutic effects. Advances in gene editing (CRISPR/Cas9) and protein engineering may further refine COL7-based therapies, offering hope for durable treatments for DEB patients.
×
